Slide 1: Ascletis Metabolic Disease Portfolio
Ascletis Metabolic Disease Portfolio August 2026
Slide 2: Disclaimer
Disclaimer ◼ The documents, opinions and materials presented and distributed in the presentation (collectively, the “Document”), which were prepared by Ascletis Pharma Inc. (the “Company”) together with its subsidiaries and affiliates (collectively, the “Group”), are provided to you solely for your
Slide 3: Ascletis: Clinical-Stage Biotech With Complete and Differentiated Obesity Portfolio
Ascletis: Clinical-Stage Biotech With Complete and Differentiated Obesity Portfolio Breadth of Ascletis’ obesity medicines is competitive for a $173.5B market1 ◼ Hong Kong Stock Exchange listed biotech (1672.HK) ◼ Approximately 220 employees in discovery, clinical development, GMP manufacturing and
Slide 4: Metabolic Diseases - Small Molecules
Metabolic Diseases - Small Molecules Product Commercial IND Target Indication Discovery Phase I Phase II Phase III Topline data and Est. Next Milestone (Modality) Rights Enabling • Initiated global Phase III for ASC30 to ASC30 enroll 4,600 people in U.S. and EU (Once-daily oral small GLP-1R Obesity
Slide 5: Metabolic Diseases - Peptides
Metabolic Diseases - Peptides Product Commercial IND Target Indication Discovery Phase I Phase II Phase III Topline data and Est. Next Milestone (Modality) Rights Enabling ASC36i • 6-fold half-life of eloralintide and MET-233i (Once-monthly to once Amylin • 32% and 91% greater relative efficacy in O
Slide 6: Ascletis Obesity Portfolio - Small Molecules
Ascletis Obesity Portfolio - Small Molecules Ascletis Competitor Ascletis Ascletis Differentiation Development Status Initiated global Phase III to enroll • Better GI tolerability to orforglipron Orforglipron ASC30 4,600 people in U.S. and EU • 15% weight loss (model-predicted) at week 72 vs 11.5% f
Slide 7: Ascletis Obesity Portfolio - Peptides
Ascletis Obesity Portfolio - Peptides Ascletis Competitor Ascletis Ascletis Differentiation Development Status Tirzepatide ASC35 FDA IND cleared • Once monthly vs Lilly once weekly (SQ peptide GLP-1/GIP) (SQ peptide GLP-1/GIP) Phase I initiated Eloralintide and ASC36_35FDC Tirzepatide FDA IND cleare
Slide 8: Oral Small Molecule GLP-1 ASC30 Global Phase III Studies Initiated
Oral Small Molecule GLP-1 ASC30 Global Phase III Studies Initiated 8
Slide 9: Two Global Phase III Studies for Oral SM GLP-1 ASC30 Initiated
Two Global Phase III Studies for Oral SM GLP-1 ASC30 Initiated ◼ Two pivotal global Phase III trials (AURORA-1 NCT07743463 and AURORA-2 NCT07743450) will enroll approximately 4,600 participants with obesity or overweight in the U.S., Europe, and Canada. ◼ Topline data from the ASC30 Phase III progra
Slide 10: Ascletis' Ultra-Long-Acting Platform (ULAP) Technology
Ascletis’ Ultra-Long-Acting Platform (ULAP) Technology for Once-Monthly to Once-Quarterly Peptides 10
Slide 11: Ultra-Long-Acting Platform (ULAP) Technology Validated Clinically and Commercially
Ultra-Long-Acting Platform (ULAP) Technology Validated Clinically and Commercially (ULAP extends t1/2 by multiple fold beyond albumin-based t1/2 extension technology) • ULAP technology suitable for small molecules, peptides, antibodies, and proteins • Proprietary depot-based technology1 allows conti
Slide 12: Lipid-Based Depot: Self-Assembling Lipid Depot (SALD)
Lipid-Based Depot: Self-Assembling Lipid Depot (SALD) ⚫ The low-viscosity solution is composed of lipid 1, lipid 2, biocompatible organic solvents, and the active pharmaceutical ingredient (API). The low-viscosity solution can be easily administered into the subcutaneous tissue using a pre-filled pe
Slide 13: QM Formulation Screening and Selection Strategy and Criteria
QM Formulation Screening and Selection Strategy and Criteria ◼ Use Ascletis’ ULAP technology to design a lot of formulations ◼ All ULAP-designed formulations were screened in monkeys since we trust monkey PK data and SQ monkey t1/2 to SQ human t1/2 relationship is well established by SQ semaglutide
Slide 14: ASC35 Observed Half-Life Approximately 14 Days, 6-Fold Longer than Tirzepatide
In Head-to-Head NHP Study, Average Observed Half-Life of ASC35 was Approximately 14 Days, 6-Fold Longer than Tirzepatide Tirzepatide and ASC35 SQ in Monkeys 10000 Concentration (ng/mL) 1000 Tirzepatide commercial formulation, SQ, 0.2 mg/kg 100 ASC35 lipid-based solution formulation, SQ, 0.5 mg/kg 10
Slide 15: Self-Assembly Lipid Depot Extends ASC36's t1/2 to 6-Fold of MET-233i
Ascletis Proprietary Self-Assembly Lipid Depot extends ASC36’s t1/2 to 6-Fold of MET-233i - Head-to-Head Study in NHPs MET-233i observed t1/2 ASC36 observed t1/2 128 h (5.3 days) post dose 768 h (32 days) post dose 10000 MET-233i buffer based non-depot formulation, SQ, 0.5 mg/kg Concentration (ng/mL
Slide 16: ASC36i and ASC35 Lipid Depot Formulations Have 6-Fold Longer t1/2
ASC36i and ASC35 Self-Assembly Lipid Depot Formulations have 6-Fold Longer t1/2 than MET-233i and Tirzepatide, Respectively Pharmacokinetic relationship between NHPs and humans is well established by multiple peptide agonists Tirzepatide GLP-1R/GIPR1 Semaglutide GLP-1R2 ASC36 amylin R ASC35 GLP-1R/G
Slide 17: Ascletis Peptide Oral Transport ENhancement Technology (POTENT)
Ascletis Peptide Oral Transport ENhancement Technology (POTENT) 17
Slide 18: Peptide Oral Transport ENhancement Technology (POTENT)
Peptide Oral Transport ENhancement Technology (POTENT) ◼ Impedes enzymatic degradation of peptides ◼ Increases gastrointestinal permeability of peptides ◼ Able to increase oral bioavailability of peptides to ≥ 3%-5% from <1% ◼ In NHPs, oral bioavailability of semaglutide in Ascletis’ POTENT formulat
Slide 19: Oral Bioavailability of Semaglutide with POTENT Formulation is 3-Fold of SNAC
Oral Bioavailability of Semaglutide with a POTENT Formulation is 3- Fold of Semaglutide with its Commercial SNAC Formulation1 Semaglutide tablet formulation developed utilizing POTENT technology body dose AUC0-72h Group Formulation Monkey weight F(%) (mg/kg) (ng*h/mL） （kg） 0.2mg/ml Semaglutide, 20mM
Slide 20: Oral Bioavailability of Tirzepatide with POTENT Formulation is 9-Fold of SNAC
Oral Bioavailability of Tirzepatide with a POTENT Formulation is 9-Fold of Tirzepatide with the SNAC Formulation1 Tirzepatide tablet formulation developed utilizing POTENT technology body dose AUC0-72h Group Formulation Monkey weight F(%) (mg/kg) (ng*h/mL） （kg） 0.2mg/ml Tirzepatide, 20mM IV dosing 0
Slide 21: ASC36 Oral Tablets Achieved Absolute Oral Bioavailability of 6.0% to 8.0% in NHPs
ASC36 Oral Tablets Achieved Absolute Oral Bioavailability of 6.0% to 8.0% in Non-Human Primates ASC36 tablet formulation developed utilizing POTENT technology body weight AUC0-inf Group Monkey dose (mg/kg) F(%) （kg） (ng*h/mL） IV dosing 0.2 mg/kg n=3 2.7 0.2 60,540 NA Oral dosing after once-daily dos
Slide 22: Thanks
Thanks Innovative cures liberate life to the fullest